Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Henry Schein, Inc. (HSIC) — XLV Health Care · S&P 500 Profile |亨利薛恩公司介紹

health-careS&P500xlv
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Henry Schein, Inc. (HSIC) — Business, History & S&P 500 Profile |亨利薛恩公司介紹

Henry Schein company profile · dental and medical distribution, specialty products and practice technology · history · financial snapshot · S&P 500 rank #493 · 亨利薛恩公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Nov 5, 2026 (Slickcharts benchmark)
Financials: FY2025 (ended Dec 27, 2025)
MARKET CAP
$9.83B
Nov 5, 2026 · Slickcharts
S&P 500 WEIGHT
0.01%
Rank #493 · Nov 5, 2026 (Slickcharts)
FY2025 NET SALES
$13.18B
+4.0% YoY · Distribution and value-added services $11.14B
FY2025 NET INCOME
$398M
Attributable to Henry Schein, Inc. · Diluted EPS $3.27

SNAPSHOT

TickerHSIC (Nasdaq)
CompanyHenry Schein, Inc.
GICS sector / industryHealth Care / Health Care Distributors
S&P 500 rank (by weight)#493 · 0.01% (Nov 5, 2026)
Sector rank (by S&P 500 weight)#60 in Health Care (Nov 5, 2026)
HeadquartersMelville, New York
Founded1932, founded by Henry Schein in Queens, New York
CEOFrederick M. Lowery (CEO, from 2026; succeeded Stanley M. Bergman)
Employees>25,000 employees (FY2025 10-K)
Market cap$9.83B (Nov 5, 2026)
SEC filingsEDGAR — CIK 0001000228

WHAT IT DOES

Henry Schein, Inc. is the world’s largest provider of health care solutions to office-based dental and medical practitioners. It distributes consumable products, equipment and pharmaceuticals to more than 1 million customers in over 30 countries, and layers higher-margin specialty products, practice-management software and value-added services on top of the distribution base. The model is a one-stop catalogue: practices order merchandise, equipment, software and services from a single supplier with next-day logistics.

FY2025 net sales were $13.18B, up 4.0% year on year, and net income attributable to Henry Schein, Inc. was $398M, or $3.27 per diluted share, against $390M, or $3.05, in FY2024. Operating income was $653M. The sales increase reflected 2.6% internal growth, 0.9% from acquisitions and a 0.5% foreign-currency benefit, per the company’s FY2025 results release.

Henry Schein reports three segments: Global Distribution and Value-Added Services (the merchandise, equipment and services engine), Global Specialty Products (own-manufactured and sourced specialty lines such as dental implants, biomaterials and orthopedics) and Global Technology (practice-management software, e-services and revenue-cycle tools). Specialty and technology carry structurally higher margins than distribution, so mix shift toward them is the profit lever.

SEGMENTS — FY2025 NET SALES

SegmentNet salesShareYoY
Global Distribution and Value-Added Services$11.14B84.5%+3.5%
Global Specialty Products$1.54B11.7%+6.8%
Global Technology$675M5.1%+7.1%
Eliminations−$173M−1.3%—
Segment net sales as disclosed for FY2025 (10-K basis); the four rows sum to net sales of $13.18B. FY2024 comparatives: Global Distribution and Value-Added Services $10,760M, Global Specialty Products $1,446M, Global Technology $630M, eliminations −$163M, total $12,673M. Segment operating income in FY2025 was led by distribution, with specialty products and technology earning higher margins on smaller sales bases.

HISTORY

YearMilestone
1932Henry Schein, a Columbia pharmacy graduate, borrows $500 and opens a pharmacy in Queens, New York — the origin of the company.
1989Stanley M. Bergman becomes CEO after the death of Jay Schein; he leads the company for more than three decades.
1995Henry Schein completes its initial public offering and lists on Nasdaq.
2026Frederick M. Lowery succeeds Stanley M. Bergman as CEO (announced in January 2026, after Bergman’s July 2025 announcement that he would step down at the end of 2025 and remain chairman).

COMPETITIVE POSITION

  • The largest dental and medical distributor globally, competing with Patterson Companies in dental, and with AmerisourceBergen (Cencora), Cardinal Health and Owens & Minor in medical distribution; its edge is catalogue breadth (hundreds of thousands of products), practice-level relationships and the attached software and services layer.
  • Distribution is a scale-and-logistics game at thin margins: group operating margin was about 5.0% in FY2025, so purchasing scale, private-label mix and delivery density decide profitability more than pricing power.
  • The growth mix is shifting up-margin: specialty products (+6.8%) and technology (+7.1%) grew faster than distribution (+3.5%) in FY2025, lifting the blended margin profile.

FINANCIAL SNAPSHOT — FY2025

Net sales$13.18B
Operating income$653M
Net income attributable to Henry Schein, Inc.$398M
Diluted EPS$3.27
FY2025 ended Dec 27, 2025 (fiscal year); Form 10-K for FY2025. Prior-year figures: net sales $12,673M, operating income $621M, net income attributable $390M, diluted EPS $3.05, so net sales grew 4.0% (as reported). Non-GAAP net income was $605M, or $4.97 per diluted share (FY2024: $4.74).

KEY RISKS

  • Margin-thin distribution risk: at roughly a 5% operating margin, cost inflation, freight or a pricing war moves earnings quickly.
  • Dental and medical demand risk: practice visits and elective dental procedures fall when households retrench, cutting merchandise volumes.
  • Cyber and systems risk: the 2023 cyber incident showed how dependent a catalogue-and-logistics model is on its ordering systems.
  • Leadership transition risk: the 2026 CEO handover from a 36-year incumbent is the company’s first succession at this scale.

WHY IT MATTERS FOR THE S&P 500

Henry Schein is the S&P 500’s dental-and-medical distribution bellwether: its internal sales growth, specialty mix and practice-technology adoption read as a gauge of office-based health care spending in the U.S. and Europe. At rank #493 by weight (0.01%) — Health Care #60 — it represents the distributor inside a health care sector dominated by insurers, pharmaceuticals and device makers.

SOURCES & METHODOLOGY

Market dataSlickcharts S&P 500 by weight (rank, weight, price, market cap — Nov 5, 2026 crawl, single source)
FinancialsForm 10-K for FY2025 (fiscal year ended Dec 27, 2025)
Sector classificationGICS via the List of S&P 500 companies (Wikipedia)
Library dataSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

Henry Schein

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號HSIC(Nasdaq)
公司Henry Schein, Inc.
GICS 板塊/行業醫療保健/Health Care Distributors
標普500排名(按權重)第493名 · 0.01%(2026 年 11 月 5 日)
板塊內排名(按標普500權重)醫療保健第60名(2026 年 11 月 5 日)
總部紐約州梅爾維爾
成立1932年,由 Henry Schein 於紐約州皇后區創立
行政總裁Frederick M. Lowery(行政總裁,自2026年起;接替 Stanley M. Bergman)
員工超過25,000名員工(FY2025 10-K)
市值$9.83B(2026 年 11 月 5 日)
SEC 文件EDGAR — CIK 0001000228

業務概覽

亨利薛恩公司是全球最大的以診所為基礎的牙科及醫療從業員醫療保健方案供應商。它向30多個國家逾100萬名客戶分銷消耗品、設備及藥品,並在分銷基礎之上疊加利潤較高的專門產品、診所管理軟件及增值服務。其模式是一站式目錄:診所可向單一供應商訂購用品、設備、軟件及服務,並享有翌日物流。

FY2025 淨銷售額為131.8億美元,同比增長4.0%;歸屬於亨利薛恩公司的淨利潤為3.98億美元,攤薄每股收益3.27美元,而 FY2024 為3.90億美元,攤薄每股收益3.05美元。營運利潤為6.53億美元。據公司 FY2025 業績公告,銷售增長來自2.6%的內部增長、0.9%的收購貢獻及0.5%的外匯利好。

亨利薛恩報告三個板塊:全球分銷及增值服務(用品、設備及服務引擎)、全球專門產品(自家製造及採購的專門產品線,如牙科植入物、生物材料及骨科產品)及全球科技(診所管理軟件、電子服務及收入週期工具)。專門產品及科技的利潤率結構上高於分銷,故組合向兩者傾斜是利潤槓桿。

板塊 — FY2025 淨銷售額

板塊淨銷售額佔比同比
全球分銷及增值服務111.4億美元84.5%+3.5%
全球專門產品15.4億美元11.7%+6.8%
全球科技6.75億美元5.1%+7.1%
抵銷−1.73億美元−1.3%—
板塊淨銷售額按 FY2025 披露(10-K 基礎);四行合計等於淨銷售額131.8億美元。FY2024 比較數字:全球分銷及增值服務107.60億美元,全球專門產品14.46億美元,全球科技6.30億美元,抵銷−1.63億美元,合計126.73億美元。FY2025 的板塊營運利潤由分銷帶領,專門產品及科技則在較小的銷售基礎上賺取較高利潤率。

歷史沿革

年份里程碑
1932年Henry Schein(哥倫比亞大學藥劑學畢業生)借入500美元,在紐約州皇后區開設藥房——公司的起源。
1989年Jay Schein 逝世後,Stanley M. Bergman 出任行政總裁,領導公司逾三十年。
1995年亨利薛恩完成首次公開發售,於納斯達克上市。
2026年Frederick M. Lowery 接替 Stanley M. Bergman 出任行政總裁(2026年1月公布;Bergman 於2025年7月已宣布將於2025年底卸任並留任主席)。

競爭地位

  • 全球最大的牙科及醫療分銷商,在牙科方面與 Patterson Companies 競爭,在醫療分銷方面與 AmerisourceBergen(Cencora)、Cardinal Health 及 Owens & Minor 競爭;其優勢在於目錄廣度(數十萬種產品)、與診所層面的關係,以及附帶的軟件及服務層。
  • 分銷是利潤微薄的規模及物流遊戲:FY2025 集團營運利潤率約5.0%,故採購規模、自有品牌組合及配送密度對盈利的影響大於定價能力。
  • 增長組合正向高利潤傾斜:FY2025 專門產品(+6.8%)及科技(+7.1%)的增長快於分銷(+3.5%),提升整體利潤率結構。

財務快照 — FY2025

淨銷售額131.8億美元
營運利潤6.53億美元
歸屬於亨利薛恩公司的淨利潤3.98億美元
攤薄每股收益3.27美元
FY2025 截至2025年12月27日(財政年度);10-K 為 FY2025 年度。上年數字:淨銷售額126.73億美元,營運利潤6.21億美元,歸屬淨利潤3.90億美元,攤薄每股收益3.05美元,故淨銷售額增長4.0%(按報告)。據公司所述,非 GAAP 淨利潤為6.05億美元,攤薄每股收益4.97美元(FY2024:4.74美元)。

主要風險

  • 利潤微薄的分銷風險:營運利潤率約5%,成本通脹、運費或價格戰都會迅速影響盈利。
  • 牙科及醫療需求風險:家庭收緊開支時,診所就診及非必要牙科程序減少,拖低用品銷量。
  • 網絡及系統風險:2023年的網絡事件顯示,目錄加物流模式高度依賴其訂購系統。
  • 領導交接風險:2026年由任職36年的行政總裁交棒,是公司首次如此規模的繼任。

對標普500的重要性

亨利薛恩是標普500中牙科及醫療分銷的風向標:其內部銷售增長、專門產品組合及診所科技採用情況,可反映美國及歐洲以診所為基礎的醫療開支。按權重排名第493位(0.01%)——醫療保健第60名——它代表醫療保健板塊內的分銷商,而該板塊由保險公司、藥廠及醫療器械商主導。

來源與方法

市場數據Slickcharts 標普500權重榜(排名、權重、價格、市值——2026 年 11 月 5 日抓取,單一來源)
財務FY2025 10-K(截至2025年12月27日的財政年度)
板塊分類GICS,據 S&P 500 公司清單(Wikipedia)
圖庫數據SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

Henry Schein

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · HSIC
Data as of Nov 5, 2026 · Financials FY2025 (10-K) · Market data Nov 2026
Previous · Federal Realty Investment Trust (FRT) — XLRE Real Estate · S&P 500 Profile |聯邦房地產投資信託公司介紹Next · BXP, Inc. (BXP) — XLRE Real Estate · S&P 500 Profile |BXP公司介紹

Entered 2026-11-04 16:59 · updated 2026-11-14 23:30 · rev 6